Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Australian Floating Rate ETF (FLOT) vs Johnson & Johnson (JNJ) Price & Performance

VanEck Australian Floating Rate ETFTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

VanEck Australian Floating Rate ETF vs Johnson & Johnson — how do they compare? VanEck Australian Floating Rate ETF trades at $50.93, while Johnson & Johnson trades at $260.86 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while VanEck Australian Floating Rate ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.

FLOTJNJ
Sector
Sector/ThematicHealth
52-Week High
$51.09$267.24
52-Week Low
$50.72$172.78
Market Cap
$626.09B
Volume
6,156,228
Enterprise Value
$654.37B
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Australian Floating Rate ETF

FLOT trades at $50.925 with minimal daily movement (+0.01%). Technical indicators show a bearish trend with all 13 moving averages signaling sell. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy as floating rate bonds like FLOT could benefit from potential rate hikes later in 2026.

FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a cash alternative with slightly higher returns than T-bills. The primary catalyst is potential Fed rate hikes, though the bearish technical picture and inflation uncertainty present near-term headwinds for price appreciation.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Australian Floating Rate ETF

FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.

Read more on FLOT

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ